225 Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study

Background A remarkable therapeutic efficacy has been demonstrated with 225Ac-prostate-specific membrane antigen (PSMA)-617 in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients. We report our experience with 225Ac-PSMA-617 therapy in chemotherapy-naive patients with advanced metastatic prostate carcinoma.